• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk-based Vaccines and the Need for Risk-based Subnational Vaccination Strategies for Introduction.基于风险的疫苗接种和制定基于风险的国家以下级别疫苗接种策略的必要性。
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S165-S171. doi: 10.1093/cid/ciaa483.
2
Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.比较伤寒 Vi 结合疫苗的策略和发生率阈值:成本效益建模研究。
J Infect Dis. 2018 Nov 10;218(suppl_4):S232-S242. doi: 10.1093/infdis/jix598.
3
Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework.利用标准化成本核算框架预测在马拉维国家免疫规划中引入伤寒结合疫苗(TCV)的成本。
Vaccine. 2022 Mar 15;40(12):1741-1746. doi: 10.1016/j.vaccine.2022.02.016. Epub 2022 Feb 10.
4
Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine-Navi Mumbai, India, 2018.2018 年,印度那格浦尔市首次在公共部门引入伤寒结合疫苗的决策与实施。
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S172-S178. doi: 10.1093/cid/ciaa597.
5
Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.孟加拉国引入伤寒结合疫苗策略的成本效益及对公共卫生的影响
Vaccine. 2024 Apr 19;42(11):2867-2876. doi: 10.1016/j.vaccine.2024.03.035. Epub 2024 Mar 25.
6
Gavi Support for Typhoid Conjugate Vaccines: Moving From Global Investments to Country Introduction.全球疫苗免疫联盟对伤寒结合疫苗的支持:从全球投资到国家引入。
Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S160-S164. doi: 10.1093/cid/ciaa342.
7
A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.预测伤寒结合疫苗在伤寒地方性中低收入国家的引入和需求,以支持疫苗引入政策和决策。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2017-2024. doi: 10.1080/21645515.2017.1333681. Epub 2017 Jun 12.
8
Cost effectiveness of typhoid vaccination in India.在印度伤寒疫苗接种的成本效益。
Vaccine. 2021 Jul 5;39(30):4089-4098. doi: 10.1016/j.vaccine.2021.06.003. Epub 2021 Jun 10.
9
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study.暴发环境中伤寒结合疫苗的成本效益分析:建模研究。
BMC Infect Dis. 2023 Mar 8;23(1):143. doi: 10.1186/s12879-023-08105-2.
10
[A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].[在意大利国家和地区层面使用RIX4414疫苗对轮状病毒进行广泛疫苗接种的全面经济评估]
Ann Ig. 2013 Jan-Feb;25(1):43-56. doi: 10.7416/ai.2013.1905.

引用本文的文献

1
Could a vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a vaccine public health value proposition, March 24 and 29, 2021.疫苗会影响长期健康结果吗?:2021年3月24日和29日关于为疫苗公共卫生价值主张提供信息的专家会议总结报告
Vaccine X. 2022 Sep 21;12:100218. doi: 10.1016/j.jvacx.2022.100218. eCollection 2022 Dec.
2
Non-selective distribution of infectious disease prevention may outperform risk-based targeting.非选择性传染病预防的分配可能优于基于风险的目标定位。
Nat Commun. 2022 May 31;13(1):3028. doi: 10.1038/s41467-022-30639-3.
3
What Drives the Value of a Vaccine?是什么决定了疫苗的价值?
Vaccines (Basel). 2022 Feb 12;10(2):282. doi: 10.3390/vaccines10020282.

本文引用的文献

1
Heterogeneity in enterotoxigenic Escherichia coli and shigella infections in children under 5 years of age from 11 African countries: a subnational approach quantifying risk, mortality, morbidity, and stunting.11 个非洲国家 5 岁以下儿童肠产毒性大肠杆菌和志贺氏菌感染的异质性:亚国家级方法量化风险、死亡率、发病率和发育迟缓。
Lancet Glob Health. 2020 Jan;8(1):e101-e112. doi: 10.1016/S2214-109X(19)30456-5. Epub 2019 Nov 14.
2
Potential impact and cost-effectiveness of future ETEC and vaccines in 79 low- and lower middle-income countries.未来肠毒素型大肠杆菌及疫苗对79个低收入和中低收入国家的潜在影响和成本效益
Vaccine X. 2019 Apr 18;2:100024. doi: 10.1016/j.jvacx.2019.100024. eCollection 2019 Aug 9.
3
A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines.《伤寒与伤寒疫苗的经济学证据回顾》
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S83-S95. doi: 10.1093/cid/ciy1122.
4
Notes from the Field: Typhoid Fever Outbreak - Harare, Zimbabwe, October 2017-February 2018.实地记录:伤寒热疫情——津巴布韦哈拉雷,2017年10月至2018年2月
MMWR Morb Mortal Wkly Rep. 2019 Jan 18;68(2):44-45. doi: 10.15585/mmwr.mm6802a5.
5
Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.2016-2018 年,来自或去往巴基斯坦的旅行者中出现了大量耐多药伤寒沙门氏菌感染。
MMWR Morb Mortal Wkly Rep. 2019 Jan 11;68(1):11-13. doi: 10.15585/mmwr.mm6801a3.
6
The Importance of Heterogeneity to the Epidemiology of Tuberculosis.结核病流行病学中异质性的重要性。
Clin Infect Dis. 2019 Jun 18;69(1):159-166. doi: 10.1093/cid/ciy938.
7
Association between floods and typhoid fever in Yongzhou, China: Effects and vulnerable groups.洪水与伤寒在中国永州的关联:影响与脆弱群体
Environ Res. 2018 Nov;167:718-724. doi: 10.1016/j.envres.2018.08.030. Epub 2018 Aug 29.
8
Breaking the inertia in coverage: Mainstreaming under-utilized immunization strategies in the Middle East and North Africa region.打破覆盖范围的惯性:在中东和北非地区推广未充分利用的免疫战略。
Vaccine. 2018 Jul 16;36(30):4425-4432. doi: 10.1016/j.vaccine.2018.05.088. Epub 2018 May 30.
9
Exploring Droughts and Floods and Their Association with Cholera Outbreaks in Sub-Saharan Africa: A Register-Based Ecological Study from 1990 to 2010.探索撒哈拉以南非洲的干旱和洪水及其与霍乱疫情爆发的关系:基于登记的 1990 年至 2010 年的生态研究。
Am J Trop Med Hyg. 2018 May;98(5):1269-1274. doi: 10.4269/ajtmh.17-0778. Epub 2018 Mar 1.
10
A Rapid Epidemiological Tool to Measure the Burden of Norovirus Infection and Disease in Resource-Limited Settings.一种用于在资源有限环境中衡量诺如病毒感染和疾病负担的快速流行病学工具。
Open Forum Infect Dis. 2017 Mar 17;4(2):ofx049. doi: 10.1093/ofid/ofx049. eCollection 2017 Spring.

基于风险的疫苗接种和制定基于风险的国家以下级别疫苗接种策略的必要性。

Risk-based Vaccines and the Need for Risk-based Subnational Vaccination Strategies for Introduction.

机构信息

Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA.

出版信息

Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S165-S171. doi: 10.1093/cid/ciaa483.

DOI:10.1093/cid/ciaa483
PMID:32725237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7388704/
Abstract

BACKGROUND

Most vaccines in the Expanded Program on Immunization are universal childhood vaccines (eg, measles and rotavirus vaccines). Other vaccines such as typhoid conjugate (TCV) and Japanese encephalitis vaccines are risk based and only used in countries where populations are at risk of these diseases. However, strategies to introduce risk-based vaccines are becoming complex due to increasing intracountry variability in disease incidence. There is a need to assess whether subnational vaccine strategies are appropriate.

CRITERIA, CHALLENGES, AND BENEFITS: Subnational strategies consider intracountry heterogeneous risk and prioritize vaccination only in those areas that are at risk; there is no intent to introduce the vaccine nationally. The following variables should be considered to determine appropriateness of subnational strategies: disease burden, outbreak potential, treatment availability and costs, cost-effectiveness, and availability of other preventive interventions. We propose criteria for each variable and use a hypothetical country considering TCV introduction to show how criteria are applied to determine if a subnational strategy is appropriate. Challenges include granularity of disease-burden data, political challenges of vaccinating only a portion of a population, and potentially higher costs of introduction. Benefits include targeted reduction of disease burden, increased equity for marginalized populations, and progress on development goals.

CONCLUSIONS

In the absence of perfect information at the national level, adopting a subnational vaccine strategy can provide country decision makers with an alternative to national vaccine introduction. Given the changing nature of communicable disease burden, subnational vaccination may be a tool to effectively avert mortality and morbidity while maximizing the use of available health and financial resources.

摘要

背景

扩大免疫规划中的大多数疫苗都是通用的儿童疫苗(例如麻疹和轮状病毒疫苗)。其他疫苗,如伤寒结合疫苗(TCV)和乙型脑炎疫苗,是基于风险的,仅在存在这些疾病风险的国家使用。然而,由于疾病发病率在国内的差异不断增加,引入基于风险的疫苗的策略变得越来越复杂。因此,有必要评估国家以下一级的疫苗策略是否合适。

标准、挑战和收益:国家以下一级的策略考虑到了国内的异质风险,并仅在那些有风险的地区优先进行疫苗接种;并没有在全国范围内引入疫苗的意图。为了确定国家以下一级策略的适宜性,应该考虑以下变量:疾病负担、暴发的可能性、治疗的可及性和成本、成本效益以及其他预防干预措施的可及性。我们为每个变量提出了标准,并使用一个考虑引入 TCV 的假设国家来展示如何应用标准来确定国家以下一级的策略是否合适。面临的挑战包括疾病负担数据的粒度、仅为部分人口接种疫苗的政治挑战以及引入疫苗的潜在更高成本。收益包括有针对性地减少疾病负担、增加边缘化人群的公平性以及在发展目标方面取得进展。

结论

在国家一级缺乏完善信息的情况下,采用国家以下一级的疫苗策略可以为国家决策者提供一种替代全国范围引入疫苗的选择。鉴于传染病负担的性质不断变化,国家以下一级的疫苗接种可能是一种有效避免死亡率和发病率的工具,同时最大限度地利用现有的卫生和财政资源。